CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
MARCAR focuses on developing early markers and molecular classifications for tumors related to non-genotoxic carcinogenesis. It aims to enhance drug safety and efficiency in drug development by using innovative experimental models.
MARCAR aims to establish reliable early markers and molecular classification of tumors in non genotoxic carcinogenesis, applying a mechanism-based approach.
Benefits are improved drug safety, more efficient drug development, and progress with 3 R issues. MARCAR focuses on rodent liver, the major target organ of non-genotoxic carcinogens (NGC).
However, this approach will facilitate predictions for other organs.
Innovative industry-relevant experimental models will be developed: (i) Transgenic mi…
NOVARTIS PHARMA AG
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
United Kingdom, Dundee
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
United Kingdom, Dundee
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
MEDIZINISCHE UNIVERSITAET WIEN
Austria, Wien
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
United Kingdom, Edinburgh
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
